Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.03 USD
Change Today +0.0002 / 0.73%
Volume 2.5M
As of 5:20 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

positiveid corp (PSID) Snapshot

Open
$0.03
Previous Close
$0.03
Day High
$0.03
Day Low
$0.03
52 Week High
10/13/14 - $0.08
52 Week Low
05/15/15 - $0.01
Market Cap
9.6M
Average Volume 10 Days
3.2M
EPS TTM
$-0.06
Shares Outstanding
350.1M
EX-Date
08/29/08
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for POSITIVEID CORP (PSID)

Related News

No related news articles were found.

positiveid corp (PSID) Related Businessweek News

View More BusinessWeek News

positiveid corp (PSID) Details

PositiveID Corporation develops molecular diagnostic systems for bio-threat detection and rapid medical testing. The company focuses on microfluidic systems for the automated preparation of and performance of biological assays for the detection of biological threats at high-value locations and analyzes samples in a medical environment. It has a portfolio of intellectual property related to sample preparation and rapid medical testing applications. The company’s M-BAND technology, developed under contract with the U.S. DHS Science & Technology directorate, is a bio-aerosol monitor with integrated systems for sample collection, processing, and detection modules. M-BAND technology analyzes air samples for the detection of pathogenic bacteria, viruses, and toxins for up to 30 days. The company’s Firefly Dx is a handheld, portable system designed to deliver molecular diagnostic results from a sample in less than 30 minutes at the point-of-need. Firefly is being developed for a range of biological detection situations, including radiation-induced cell damage within the human body and strains of influenza, and has demonstrated the ability to detect and identify other common pathogens and diseases, such as E. coli, methicillin-resistant staphylococcus aureus, and human papilloma virus. The company was formerly known as VeriChip Corporation and changed its name to PositiveID Corporation in November 2009. PositiveID Corporation was founded in 2001 and is headquartered in Delray Beach, Florida.

9 Employees
Last Reported Date: 03/30/15
Founded in 2001

positiveid corp (PSID) Top Compensated Officers

Chairman, Chief Executive Officer and Acting ...
Total Annual Compensation: $605.0K
President
Total Annual Compensation: $472.5K
Compensation as of Fiscal Year 2014.

positiveid corp (PSID) Key Developments

PositiveID Corporation and GenArraytion Inc Enters into Agreement to Partner and Evaluate GenArraytion Assays on PositiveID Firefly Dx PCR Breadboard Prototype Pathogen Detection System

PositiveID Corporation and GenArraytion Inc. announced that they have entered into an agreement to partner and evaluate GenArraytion assays on PositiveID Firefly Dx PCR breadboard prototype pathogen detection system. Firefly Dx is designed to provide real-time, accurate diagnostic results in a handheld device, thereby leading to treatment scenarios at the point of need that are not possible with existing systems, which require lab-based equipment and can take hours or even days to provide results. Firefly's applications include point of need, lab quality, detection of pathogenic organisms; agricultural and food screening in both domestic sectors and developing countries; and detection of biological agents associated with weapons of mass destruction. GenArraytion MultiFLEX Bioassays for clinically relevant pathogens and bio-threat agents provide a significant advance in multiplexing flexibility, with up to 20 DNA and/or RNA targets in a single assay panel that can be mixed and matched. They are readily configurable, highly specific and sensitive multiplex PCR assays ready for use in real-time and bead based end point platforms. MultiFLEX Bioassays are developed for clinical pathogens and veterinary disease agents as well as food or water-borne pathogens and biological threats.

PositiveID Eyes Acquisitions

PositiveID Corporation (OTCPK:PSID) is planning to complete one or more strategic acquisitions, bringing additional revenue and products to broaden PositiveID's biological detection and diagnostics business. "We believe that the progress we have made with the testing and development of our Firefly Dx pathogen detection system is noteworthy, and as such we are focused on increasing our collaboration with large government and commercial partners," stated William J. Caragol, Chairman and Chief Executive Officer of PositiveID. “Not only do we believe we will report a significant increase in revenue compared to last year, but we also believe we will complete one or more product acquisitions this year, which will provide additional revenue and contribute to both our top and bottom lines going forward."

PositiveID Corporation Announces Tests 12 Different Assays on its Firefly Dx Prototype System

PositiveID Corporation announced that it has now successfully tested 12 different assays on its Firefly Dx breadboard prototype PCR (polymerase chain reaction) pathogen detection system. Using both its own as well as third-party assays, Firefly Dx successfully detected all the pathogens it tested for in less than 20 minutes. All tests were performed on the Firefly Dx breadboard, which is significantly faster than standard laboratory equipment and protocols. A design advantage of Firefly Dx is that it does not require additional equipment or separate steps for sample preparation and purification, unlike current lab-based equipment, thus reducing time to results as well as cost per test. In addition, there is significantly less chance of sample contamination compared to existing testing methods. The company's Firefly Dx is designed to provide real-time, accurate diagnostic results in a handheld device, thereby leading to treatment scenarios at the point of need that are not possible with existing systems, which require lab-based equipment, highly trained personnel, and can take hours or even days to provide results. Firefly's applications include point-of-need, lab-quality, detection of pathogenic organisms; agricultural screening in both domestic sectors and developing countries; and detection of biological agents associated with weapons of mass destruction.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PSID:US $0.03 USD +0.0002

PSID Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ALR Technologies Inc $0.0035 USD 0.00
Medtronic PLC $71.55 USD +2.02
Microsoft Corp $43.36 USD +1.54
View Industry Companies
 

Industry Analysis

PSID

Industry Average

Valuation PSID Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact POSITIVEID CORP, please visit www.psidcorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.